Innovator Growth Accelerated Plus ETF - July Price & Performance (QTJL)

Thermo Fisher Scientific's stock climbed over 4% following a first-quarter earnings beat, with adjusted EPS reaching $5.15 and revenue guidance for 2025 raised to $43.3–$44.2 billion. Despite the rally, shares remain near a 52-week low, reflecting lingering market caution amid a challenging six-month period.12

Innovator Capital Management plans to close multiple Defined Outcome ETFs, including the U.S. Equity Accelerated and Premium Income series, with trading halts and liquidations set for early April. The closures coincide with the funds’ outcome periods ending and impact a small portion of the firm’s total managed assets.34

MSCI reported strong first-quarter results, beating EPS forecasts and highlighting robust growth in non-ETF assets. Management noted that client activity remains steady despite broader market volatility, and retention rates are holding at historical averages, supporting a positive outlook for the remainder of 2025.56